Promoter holding
64.27%
IP
Intas Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Intaspharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Intaspharma — 360° Intelligence Report
Generated from MCA filings & public records78/100
Trust Score
Low Risk
Intaspharma is assessed as Low Risk with a Trust Score of 78/100. Intaspharma is an active public limited indian non-government company incorporated in 1985, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Intas Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
78/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AA+).
Charges position: 1 open (4.50 cr) · 81 satisfied (7,924.94 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 3 | 48.0 cr |
| State Bank Of India | 10 | 48.0 cr |
| Indusind Bank Ltd. | 4 | 48.0 cr |
| Idbi Trusteeship Services Limited | 3 | 48.0 cr |
| Citi Bank N.A. | 4 | 48.0 cr |
| Standard Chartered Bank | 1 | 48.0 cr |
Compliance Score: 42/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: DRT, EPFO.
- Litigation present in 5 court forum(s).
- Delayed payments to MSME suppliers disclosed (99 disclosure(s)).
- 26 active GST registration(s).
Legal cases on record (5)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| URMISH HASMUKH CHUDGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HASMUKH CHUDGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARCHANA RAVINDRARAI DHOLAKIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAYESH SHANTILAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATESH RATNASAMI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BINISH HASMUKH CHUDGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANOJ NARAYANAN NAIR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Jitesh Kishorekumar Gadhia | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY KUKREJA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIMISH HASMUKH BHAI CHUDGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Abhimanyu Ojha | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 11 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 7 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Accord Biopharma Inc. (usa) | Subsidiary Company | 74.00% |
| Accord Farma S.a. De C.v. (mexico) | Subsidiary Company | 74.00% |
| Accord Farmaceutica Ltda (brazil) | Subsidiary Company | 74.00% |
| Accord Healthcare (proprietary) Limited (south Africa) | Subsidiary Company | 74.00% |
| Accord Healthcare (thailand) Limited | Subsidiary Company | 74.00% |
| Accord Healthcare Ab (sweden) | Subsidiary Company | 74.00% |
| Accord Healthcare Ag (switzerland) | Subsidiary Company | 74.00% |
| Accord Healthcare B.v. (netherlands) | Subsidiary Company | 74.00% |
| Accord Healthcare Bvba (belgium) | Subsidiary Company | 74.00% |
| Accord Healthcare France Sas (france) | Subsidiary Company | 74.00% |
Key managerial personnel: URMISH HASMUKH CHUDGAR (Managing Director) · JAYESH SHANTILAL SHAH (Whole-time director) · BINISH HASMUKH CHUDGAR (Managing Director) · NIMISH HASMUKH BHAI CHUDGAR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (42/100).
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 14.31 cr.
5 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence67/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 4.50 cr already registered.
- Compliance gaps should be priced into terms.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events08 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
11 Oct 2024
Director appointed
Abhimanyu Ojha (Cfo)
01 Oct 2024
Charge satisfied
Others
30 Sep 2024
Director ceased
BINISH HASMUKH CHUDGAR
19 Sep 2024
Director appointed
Jitesh Kishorekumar Gadhia (Additional Director)
30 Jul 2023
Director ceased
ARCHANA RAVINDRARAI DHOLAKIA
14 Jun 2023
Director appointed
ARCHANA RAVINDRARAI DHOLAKIA (Director)
30 Nov 2022
Director ceased
TUSHAR DHANSUKH SHROFF
30 Nov 2021
Charge satisfied
Others
04 Aug 2021
Charge satisfied
Others
31 Mar 2021
Share transfer (FY 2021)
66570.00000000 shares to Canary Investments Limited
Share transfer (FY 2021)
3192947.00000000 shares to Canary Investments Limited
Share transfer (FY 2021)
189707.00000000 shares to Link Investment Trust II
01 Oct 2020
Securities allotted
23077 Equity Shares - 2.31 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
11 active director(s) / partner(s); board looks stable and experienced.
26 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of AA+ from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
235 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Pg | U24240MH1989PTC050398 | Mumbai, Maharashtra, India |
| Rb | U74999HR1951PTC075277 | Gurgaon, Haryana, India |
| Dow | U24239MH1998PTC113551 | Thane, Maharashtra, India |
| Mylan | U24231TG1984PLC005146 | Hyderabad, Telangana, India |
| Indorama India Private Limited | U74999WB2017FTC222920 | Salt Lake, West Bengal, India |
| Basf | L33112MH1943FLC003972 | Mumbai, Maharashtra, India |
| Upl | L24219GJ1985PLC025132 | Distt. Valsad, Gujarat, India |
| Hpcl-Mittal Energy | U23201PB2000PLC024126 | Bhatinda, Punjab, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Intaspharma before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Intaspharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Intaspharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 78/100, distress signals and MSME payment-delay disclosures - know whether Intaspharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (5 case(s) on record), regulatory flags, charge documents trail and director networks for Intaspharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Intaspharma an active company?
Intaspharma has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).
Is Intaspharma financially healthy?
Intaspharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Intaspharma?
Its overall Trust Score is 78/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Intaspharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 11 active director(s) are on record.
Does Intaspharma have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 81 earlier charge(s) stand satisfied.
Is Intaspharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).
Is it risky to lend to Intaspharma?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
